Pharmacogenomics for Better Treatment of Fungal Infections in Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

November 1, 2024

Primary Completion Date

June 1, 2026

Study Completion Date

September 2, 2026

Conditions
Fungal InfectionHaematological MalignancyBlood CancerInfectious Disease
Interventions
OTHER

genotype-directed dosing with dosing software based on therapeutic drug monitoring

Genotype-directed dosing with dosing software based on therapeutic drug monitoring

Trial Locations (7)

2145

Westmead Hospital, Sydney

3053

Peter MacCallum Cancer Centre, Melbourne

4029

Royal Brisbane & Women's Hospital, Brisbane

Children's Hospital Queensland, South Brisbane

5000

Royal Adelaide Hospital, Adelaide

21452031

Sydney Children's Hospital Network, Sydney

908109-1024

Fred Hutchinson Cancer Centre, Seattle

All Listed Sponsors
collaborator

Metro North Hospital and Health Service

UNKNOWN

collaborator

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

OTHER

collaborator

University of Sydney

OTHER

collaborator

Western Sydney Local Health District

OTHER

collaborator

Sydney Children's Hospitals Network

OTHER

collaborator

Peter MacCallum Cancer Centre, Australia

OTHER

collaborator

University of Melbourne

OTHER

collaborator

Queensland Children's Hospital

OTHER_GOV

collaborator

Royal Adelaide Hospital

OTHER

collaborator

Pathology Queensland

UNKNOWN

collaborator

Royal Brisbane and Women's Hospital

OTHER_GOV

lead

The University of Queensland

OTHER

NCT06510699 - Pharmacogenomics for Better Treatment of Fungal Infections in Cancer | Biotech Hunter | Biotech Hunter